Cargando…

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

A high expression level of epidermal growth factor receptor (EGFR)/HER1 has been suggested to lead to a shorter survival time and resistance to endocrine therapy in patients with breast cancer. To test the hypothesis that inhibition of the EGFR signalling pathway affects the antitumour effect of end...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, S, Kurebayashi, J, Otsuki, T, Yamamoto, Y, Tanaka, K, Sonoo, H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395342/ https://www.ncbi.nlm.nih.gov/pubmed/14710235 http://dx.doi.org/10.1038/sj.bjc.6601504

Ejemplares similares

ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data
por: Robertson, J F R
Publicado: (2001)

Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines
por: Woode, Denzel R., et al.
Publicado: (2012)

ICI 182,780 has agonistic effects and synergizes with estradiol-17 beta in fish liver, but not in testis
por: Pinto, Patrícia IS, et al.
Publicado: (2006)

Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism
por: Kendall, Sherie L, et al.
Publicado: (2005)

A transcriptomics model of estrogen action in the ovine fetal hypothalamus: evidence for estrogenic effects of ICI 182,780
por: Rabaglino, Maria Belen, et al.
Publicado: (2018)

ICI 182,780 Attenuates Selective Upregulation of Uterine Artery Cystathionine β-Synthase Expression in Rat Pregnancy
por: Bai, Jin, et al.
Publicado: (2023)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
por: Sewell, J M, et al.
Publicado: (2002)

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
por: Magné, N, et al.
Publicado: (2003)

17β-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes
por: Jallow, Fatou, et al.
Publicado: (2018)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells
por: Muler, Mari Luminosa, et al.
Publicado: (2020)

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
por: Magné, N, et al.
Publicado: (2002)

The antiestrogen ICI 182,780 induces early effects on the adult male mouse reproductive tract and long-term decreased fertility without testicular atrophy
por: Cho, Hyun Wook, et al.
Publicado: (2003)

The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules
por: Oliveira, Cleida A, et al.
Publicado: (2003)

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
por: DeFriend, D. J., et al.
Publicado: (1994)

Reduction of post injury neointima formation due to 17β-estradiol and phytoestrogen treatment is not influenced by the pure synthetic estrogen receptor antagonist ICI 182,780 in vitro
por: Finking, Gerald, et al.
Publicado: (2002)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling
por: Martin, L-A, et al.
Publicado: (2005)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
por: Magné, N, et al.
Publicado: (2002)

Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182(R)-6
por: Jensen, B L, et al.
Publicado: (1999)

ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
por: Williams, K J, et al.
Publicado: (2002)

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
por: Maddineni, S B, et al.
Publicado: (2005)

Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by antioestrogens in KPL-3C human breast cancer cells.
por: Kurebayashi, J., et al.
Publicado: (1997)

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
por: Mu, Xin-Lin, et al.
Publicado: (2004)

Effects of ICI 182780 on estrogen receptor expression, fluid absorption and sperm motility in the epididymis of the bonnet monkey
por: Shayu, Deshpande, et al.
Publicado: (2005)

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
por: Howell, A., et al.
Publicado: (1996)

Non-Steroidal Antioestrogens
por: Barnes, D.
Publicado: (1983)

The effects of estrogen, its antagonist ICI 182, 780, and interferon-tau on the expression of estrogen receptors and integrin alphaV beta 3 on cycle day 16 in bovine endometrium
por: Kimmins, Sarah, et al.
Publicado: (2003)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
por: Cappuzzo, F, et al.
Publicado: (2003)

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

Preventive effects of antioestrogen on mammary and pituitary tumorigenesis in rats.
por: Sumi, C., et al.
Publicado: (1984)

Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect
por: Kurebayashi, J, et al.
Publicado: (1999)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Hypoxia Reduces Hormone Responsiveness of Human Breast Cancer Cells
por: Kurebayashi, Junichi, et al.
Publicado: (2001)

On the causes of fevers (1839)
por: Pelling, Margaret
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_hag8b14uk8je4atc2eokigsnf9